Tax incentive granted by the federal government
Receita Federal do Brasil formalized the authorization of Opella Healthcare Brazil Ltda. to participate in the special regime that allows the use of presumed credits from the PIS/Pasep and Cofins contributions in the medicines segment. The decision was made official through publication in the Diário Oficial da União, marking another step in the tax stimulus policy aimed at the pharmaceutical sector.
What changes for the company
With the measure, the company now has a mechanism that reduces the tax burden on its operations by allowing it to use presumed credits from these two contributions. In practice, the benefit tends to directly impact the company's cost structure, which may be reflected in the final price of pharmaceutical products.
- Presumed credit: a modality that waives individualized proof of credits, simplifying the tax calculation.
- Scope: applies to the PIS/Pasep and Cofins contributions.
- Covered sector: the pharmaceutical industry and trade, according to the rules of the specific regime.
Context of the pharmaceutical sector
Special tax regimes for medicines exist precisely to ease the tax pressure on a segment considered strategic for public health. By authorizing companies such as Opella Healthcare, the government seeks to make the production and sale of medicines more competitive in the domestic market.
The authorization is not automatic: it depends on analysis and approval by Receita Federal, which assesses whether the company meets the criteria set out in the legislation. Only after this endorsement can the company effectively use the credits.
Next steps
Publication in the Diário Oficial da União gives the decision legal validity and allows Opella Healthcare Brazil Ltda. to operate under the rules of the special regime. The expectation is that the benefit will translate into greater tax efficiency for the company throughout its activities in the country.
The measure is part of a set of incentive policies that have been applied to the health sector, with the stated objective of stimulating the supply of medicines and reducing cost bottlenecks in the production chain.